Roche's Susvimo and AbbVie's Rinvoq Receive Regulatory Approvals

The U.S. Food and Drug Administration approved Roche’s Susvimo (ranibizumab implant) for neovascular, or “wet,” age‑related macular degeneration. The implant delivers continuous medication and can reduce treatment frequency to as few as two procedures per year. Carl Regillo, MD, of Wills Eye Hospital said, “Susvimo represents a major advancement in the treatment of retinal disease.”

The European Commission granted approval for AbbVie’s Rinvoq (upadacitinib) to treat non‑segmental vitiligo in adults and adolescents, making it the first systemic therapy for the condition in the EU. Roopal Thakkar, EVP and CSO at AbbVie, noted, “People with vitiligo have limited treatment options, and Rinvoq’s approval addresses a significant need for patients across Europe.”